RYSTIGGO
These highlights do not include all the information needed to use RYSTIGGO safely and effectively. See full prescribing information for RYSTIGGO. RYSTIGGO (rozanolixizumab-noli) injection, for subcutaneous use Initial U.S. Approval: 2023
3c0eb8c2-c042-4954-b451-3baa77f5e6d1
HUMAN PRESCRIPTION DRUG LABEL
Jun 30, 2023
UCB, Inc.
DUNS: 028526403
Products 4
Detailed information about drug products covered under this FDA approval, including NDC codes, dosage forms, ingredients, and administration routes.
ROZANOLIXIZUMAB
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (1)
ROZANOLIXIZUMAB
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (1)
ROZANOLIXIZUMAB
Product Details
FDA regulatory identification and product classification information
FDA Identifiers
Product Classification
Product Specifications
INGREDIENTS (1)
ROZANOLIXIZUMAB
Product Details
FDA regulatory identification and product classification information